Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Gastrointestinal Stromal Tumors 2 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Recurrence 1 Ovarian Neoplasms 1 Neurofibrosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Gemcitabine 15 pembrolizumab 13 Doxorubicin 13 Radiotherapy 12 Docetaxel 9 Nivolumab 8 Filgrastim 7 Cyclophosphamide 7 pazopanib 6 Ifosfamide 6 130-nm albumin-bound paclitaxel 5 Temozolomide 4 Irinotecan 4 Ipilimumab 4 Imatinib Mesylate 4 Albumin-Bound Paclitaxel 4 talimogene laherparepvec 3 surufatinib 3 pegfilgrastim 3 eribulin 3 atezolizumab 3 Vinorelbine 3 Sirolimus 3 Peripheral Blood Stem Cell Transplantation 3 PM 01183 3 Drug Therapy 3 Cisplatin 3 toripalimab 2 spartalizumab 2 selinexor 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Sarcoma × pexidartinib × Clear all

NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡